Show simple item record

dc.contributor.authorElias, Rawaden_US
dc.contributor.authorGiobbie-Hurder, Anitaen_US
dc.contributor.authorMcCleary, Nadine Jacksonen_US
dc.contributor.authorOtt, Patricken_US
dc.contributor.authorHodi, F. Stephenen_US
dc.contributor.authorRahma, Osamaen_US
dc.date.accessioned2018-05-30T17:02:14Z
dc.date.issued2018en_US
dc.identifier.citationElias, Rawad, Anita Giobbie-Hurder, Nadine Jackson McCleary, Patrick Ott, F. Stephen Hodi, and Osama Rahma. 2018. “Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.” Journal for Immunotherapy of Cancer 6 (1): 26. doi:10.1186/s40425-018-0336-8. http://dx.doi.org/10.1186/s40425-018-0336-8.en
dc.identifier.issnen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:37067823
dc.description.abstractBackground: Immune checkpoint inhibitors targeting PD-1/PD-L1 pathway demonstrated promising activities in variety of malignancies, however little is known regarding their efficacy in adults aged ≥65 years. Methods: We conducted a systematic review and a study-level meta-analysis to explore efficacy of ICIs based on age, younger vs older than 65 years. We included in this analysis randomized controlled phase II or III studies in patients with metastatic solid tumors that compared efficacy of PD-1 or PD-L1 inhibitors to a non-PD-1/PD-L1 inhibitor. Aggregated estimates of overall survival (OS) and progression-free survival (PFS) are based on random/mixed effects (RE) models to allow for heterogeneity between the studies. Results: Initial search identified 53 articles, 17 were randomized controlled trials that compared nivolumab, pembrolizumab or atezolizumab to chemotherapy or targeted therapy. Only 9 trials reported hazard ratiios (HR) for OS based on age and were included in this meta-analysis. Out of those studies seven reported HR for PFS but only 4 studies included subgroup-analysis based on age for PFS. The overall estimated random-effects HR for death was 0.64 with 95% CI of 0.54–0.76 in patients ≥65 years vs. 0.68 with 95% CI of 0.61–0.75 in patients < 65 years. The overall estimated random-effects for HR for progression was 0.74 with 95% CI of 0.60–0.92 in patients ≥65 years vs. 0.73 with 95% CI of 0.61–0.88 in patients < 65 years. Conclusions: PD-1 (nivolumab and pembrolizumab) and PD-L1 (atezolizumab) inhibitors had comparable efficacy in adults younger vs ≥ 65 years.en
dc.language.isoen_USen
dc.publisherBioMed Centralen
dc.relation.isversionofdoi:10.1186/s40425-018-0336-8en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885356/pdf/en
dash.licenseLAAen_US
dc.titleEfficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysisen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalJournal for Immunotherapy of Canceren
dash.depositing.authorMcCleary, Nadine Jacksonen_US
dc.date.available2018-05-30T17:02:14Z
dc.identifier.doi10.1186/s40425-018-0336-8*
dash.contributor.affiliatedMcCleary, Nadine
dash.contributor.affiliatedRahma, Osama
dash.contributor.affiliatedOtt, Patrick


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record